文章核心观点 - 分析师给予Castle Biosciences, Inc.(CSTL)的平均目标价为33.33美元,较当前股价上涨36.2%,表明公司股价有较大上涨潜力 [1][2] - 分析师对公司未来盈利前景持乐观态度,最近30天内一家分析师上调了当年盈利预测,没有下调,显示公司业绩有望超预期 [9][10] - 公司目前被评为Zacks Rank 2(买入),处于行业前20%,这也表明公司短期内有望上涨 [11] 公司情况总结 - 公司股价在过去4周内上涨23.3% [1] - 分析师给出的目标价区间为25-40美元,标准差为4.69美元,表明分析师对公司前景预测一致性较高 [2][7] - 分析师给出的目标价平均值较当前股价高36.2% [1] - 分析师给出的目标价中,最乐观的预测公司股价可上涨63.4% [2] 行业情况总结 - 分析师给出的股票目标价并不能完全准确预测股价走势,存在一定偏差 [3][5][8] - 分析师给出目标价的动机可能受到其所在券商的商业利益影响,存在一定程度的利益冲突 [6] - 但分析师预测一致性较高,仍可作为进一步研究公司基本面驱动因素的参考依据 [7]

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- ...

文章核心观点 - 分析师给予Castle Biosciences, Inc.(CSTL)的平均目标价为33.22美元,较当前价格上涨36.1%,表明该股票仍有较大上涨空间 [1][2] - 分析师普遍看好公司未来的盈利前景,一个月内有一个盈利预测上调,而没有下调,预示着公司业绩有望超预期 [10][11] - 公司目前被评为Zacks Rank 2(买入),处于行业前20%,这也表明其短期内有望上涨 [12] 公司相关 - 分析师给予的目标价格存在较大差异,标准差为4.68美元,表明分析师对该股价格预测存在较大分歧 [2] - 分析师设置目标价格往往存在偏高倾向,主要是为了吸引投资者关注公司,而非真实反映公司价值 [6] - 尽管分析师目标价格不太可靠,但其预测的价格走向仍可作为进一步研究的参考依据 [8] 行业相关 - 分析师对公司未来盈利的乐观预期,反映了其对公司基本面的看好 [10] - 盈利预测的上调往往与股价短期走势呈正相关,这是一个较为可靠的指标 [10]

文章核心观点 - 短期投资或交易的关键是抓住趋势 [1] - 确保股票价格趋势的持续性很重要,需要关注基本面因素和盈利预测修正等 [2] - 通过"近期价格强度"筛选可以找到符合趋势投资条件的股票,如Castle Biosciences, Inc. (CSTL) [3] 公司概况 - CSTL在过去12周内股价上涨1.7%,反映出投资者持续看好其上涨潜力 [4] - 过去4周内股价上涨16.9%,显示趋势仍在持续 [5] - CSTL当前股价处于52周高低价区间的86.4%,接近突破 [6] 基本面分析 - CSTL目前评级为Zacks Rank 2(买入),属于业内前20%的股票 [7] - Zacks Rank评级体系历史表现出色,Rank 1股票平均年收益率达25% [8] - 券商给予CSTL"强烈买入"的平均评级,对其近期表现持乐观态度 [8]

Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR & Corporate Affairs Derek Maetzold - President, CEO, Founder & Director Frank Stokes - CFO Conference Call Participants Subbu Nambi - Guggenheim Kyle Mikson - Canaccord Genuity Corey Rosenbaum - Scotiabank Thomas Flaten - Lake Street Paul Knight - KeyBanc Mason Carrico - Stephens Catherine Schulte - Baird Operator Good afternoon, and welcome to Castle Biosciences First ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-38984 CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Del ...

Exhibit 99.1 Castle Biosciences Reports First Quarter 2024 Results Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $255-265 million from $235-240 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - May 2, 2024--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fir ...

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an expert consensus article in the Journal of Clinical and Aesthetic Dermatology (JCAD) related to the utility of its DecisionDx-SCC test in clinical decision-making regarding the use of ART.2 The consensus guidelines outline a recommended risk-based workflow that integrates DecisionDx-SCC and AJCC8 staging into current ...

Castle Biosciences公司新数据发布 - Castle Biosciences公司宣布了新数据，强调了其IDgenetix药物基因组学（PGx）测试在指导65岁及以上患有心理健康状况的患者药物推荐方面的价值[1] - IDgenetix是一种先进的3合1 PGx测试，结合了遗传信息、药物相互作用和生活方式因素，以制作报告，帮助临床医生为患有抑郁症、焦虑症和其他神经精神疾病的患者选择最佳药物[2] - 所有研究中的患者都具有可能影响至少15个基因中3个基因的药物选择的遗传多态性，其中66%的药物推荐是由药物-基因相互作用引起的，而药物-药物相互作用和生活方式因素占34%（27%和7%）[3]

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company’s executive management is scheduled to present a company overview at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 11:15 a.m. Eastern time. A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir. ...